Content by National Institute of Allergy and Infectious Diseases
|2 min read
Phase 1 Trial of Universal Flu Vaccine Candidate Begins
Nanoparticle vaccine targets six flu strains and may need to be taken less than once a year
|2 min read
New Details on Idiopathic CD4 Lymphocytopenia Uncovered
There is no known cause for this rare immune disorder and no evidence of person-to-person transmissivity
|2 min read
Mucosal COVID-19 Vaccines: Potential and Challenges
Research needed to propel mucosal vaccine development is a priority
|3 min read
Marburg Vaccine Shows Promising Results in a First-in-Human Study
Good safety profile may help MARV vaccine efficiently quell emergency outbreaks
|2 min read
Developing Mucosal Vaccines for Respiratory Viruses
NIAID experts offer perspective on next-generation approaches
|1 min read
Experts Review Monkeypox Challenges
The authors note that the epidemiologic pattern of the outbreak of monkeypox resembles that of the early cases of AIDS
|3 min read
NIH Launches Clinical Trial of Universal Influenza Vaccine Candidate
The first-in-human, Phase 1 trial will assess the safety and protection of a universal influenza vaccine
|3 min read
Peer-Reviewed Report on Moderna COVID-19 Vaccine Published
Based on Phase 3 trial results, the vaccine was 94.1 percent efficacious in preventing symptomatic COVID-19
|2 min read
NIAID Establishes Centers for Research in Emerging Infectious Diseases
Global network to focus on spillover potential
|2 min read
COVID-19 Response: Steps to Expand and Improve Antibody Tests
NIH workshop attendees review capabilities, limits of SARS-CoV-2 serology testing
|4 min read
Clinical Trial of Investigational Vaccine for COVID-19 Begins
Study enrolling Seattle-based healthy adult volunteers
|3 min read
